INNOVATIVE
WORLD

ISSN: 3030-3591
Impact Factor: SJIF X.XXX

ORIENTAL JOURNAL OF MEDICINE AND NATURAL SCIENCES

Open Access, Peer Reviewed Journal

Scientific Journal

- Medicine
- Pharmaceuticals
- Biology
- Chemistry
- Geology
- Agriculture

☎ +998 33 0178868
www.innoworld.net



AI-DRIVEN METAGENOMIC ANALYSIS TO UNCOVER MICROBIAL INFLUENCES ON CANCER DEVELOPMENT

Ashurov Abdukhamid Kholikjon Ugli
Departent of general surgery, Fergana Medical Institue of Public Health, Fergana, Uzbekistan
talaba00719941995@gmail.com

Abstract

Artificial intelligence (AI)-driven metagenomic analysis is revolutionizing our understanding of the microbial influences on cancer development. The human microbiome, particularly the gut microbiota, plays a pivotal role in modulating immune responses, inflammation, and metabolic pathways, all of which are crucial in cancer initiation and progression. Advances in metagenomic sequencing, combined with AI techniques such as machine learning and deep learning, have facilitated the identification of microbial biomarkers and survival subtypes across diverse cancer types. These approaches provide insights into microbiome-immune interactions and their impact on treatment outcomes, including chemotherapy and immunotherapy efficacy. Despite the transformative potential, challenges persist, such as dataset complexity, biases, and the interpretability of AI models. Addressing these issues through explainable AI and diversified databases will enhance clinical integration and precision oncology. This article highlights the role of AI in unlocking the complex interplay between the microbiome and cancer, paving the way for innovative diagnostics, personalized therapies, and improved patient outcomes.

Keywords: AI-driven metagenomics, cancer microbiome, microbial biomarkers, precision oncology, personalized medicine

Introduction

AI-driven metagenomic analysis has emerged as a pivotal tool in uncovering the microbial influences on cancer development, offering insights into the complex interactions between the microbiome and cancer. The human microbiome, particularly the gut microbiota, plays a significant role in cancer initiation and progression by modulating immune responses, influencing inflammation, and affecting metabolic processes(Istuti Saraswat & Anjana Goel, 2024; Md. Fakruddin et al., 2023). Dysbiosis, or microbial imbalance, can disrupt the epithelial barrier, promote inflammation, and facilitate carcinogenesis(Istuti Saraswat & Anjana Goel, 2024; Л. Г. Соленова et al., 2024). Advanced metagenomic techniques, such as 16S rRNA sequencing and multi-omics approaches, have been instrumental in characterizing the tumor microbiome and identifying microbial biomarkers associated with various cancers(Istuti Saraswat & Anjana Goel, 2024; Ivania Valdés et al., 2024). AI and machine learning have further enhanced the analysis of microbiome data, enabling the identification of microbiome quantitative trait loci (mbQTLs) that link genetic variants to microbial abundances across different cancer types(İlhami KİZİROĞLU, 2023; "Pan-Cancer Analysis of Microbiome Quantitative Trait Loci," 2022). These technologies have also facilitated the discovery of survival subtypes and potential therapeutic targets by integrating microbial profiles with host gene expressions(Haohong Zhang et al., 2024). The tumor microbiome's influence extends to treatment outcomes, where it can modulate the efficacy and toxicity of chemotherapy and immunotherapy. For instance, specific microbes have been linked to treatment-related toxicity and immune modulation, affecting patient responses to cancer therapies(Saksham Garg et al., 2023; Sona Ciernikova et al., 2023). AI-driven analyses have also revealed interactions between the tumor microbiome and immune pathways, such as the HIF-1 signaling pathway, which may offer new avenues for personalized cancer treatment(Haohong Zhang et al., 2024). Overall, AI-driven metagenomic analysis provides a comprehensive framework for understanding the multifaceted role of the microbiome in cancer, highlighting its potential in developing personalized therapeutic strategies and improving clinical outcomes(İlhami KİZİROĞLU, 2023; *Machine Learning on Microbiome Research in Gastrointestinal Cancer*, 2023).

Microbiome and cancer development

The microbiome plays a multifaceted role in cancer development through its influence on immune balance, metabolic homeostasis, and dysbiosis-related mechanisms such as inflammation and immune modulation. The gut microbiota, a significant component of the human microbiome, is crucial in maintaining immune homeostasis and modulating the tumor microenvironment, which can either suppress or promote tumorigenesis depending on the microbial composition and its interactions with the host immune system(Istuti Saraswat & Anjana Goel, 2024; Zsuzsánna Réthi-Nagy & Szilvia Juhász, 2024). Dysbiosis, or microbial imbalance, is linked to chronic inflammation and immune dysfunction, creating a pro-inflammatory environment conducive to cancer progression, as seen in colorectal cancer (CRC) and head and neck cancer (HNC)(Veeksha V Shetty & Shilpa S. Shetty, 2024; Zuzanna Chilimoniuk et al., 2024). Specific bacterial taxa, such as Fusobacterium nucleatum and Bacteroides fragilis, have been associated with CRC through mechanisms involving inflammation and genotoxin production(Zuzanna Chilimoniuk et al., 2024). Moreover, the gut microbiome influences cancer treatment outcomes by modulating drug metabolism and immune responses, affecting the efficacy of chemotherapy and immunotherapy(Istuti Saraswat & Anjana Goel, 2024; Sona Ciernikova et al., 2023). For instance, dysbiosis can lead to immune suppression and reduced response to immune checkpoint blockade, as observed in lung cancer models(Zahraa Rahal et al., 2023). The microbiome's ability to modulate immune cells within the tumor microenvironment further underscores its role in cancer progression and treatment response(Liu et al., 2024; Saksham Garg et al., 2023). Therapeutic interventions targeting the microbiome, such as probiotics, prebiotics, and fecal microbiota transplantation, aim to restore microbial balance and enhance treatment efficacy(Zhou Chen et al., 2023; Zsuzsánna Réthi-Nagy & Szilvia Juhász, 2024). These strategies highlight the potential of microbiome-based therapies to improve cancer prevention and treatment by leveraging the microbiome's complex interactions with the host immune system and metabolic pathways(Saksham Garg et al., 2023; Zhou Chen et al., 2023). Understanding these intricate relationships is crucial for developing personalized cancer therapies that optimize the microbiome's beneficial effects while mitigating its adverse impacts on cancer development and treatment outcomes(Istuti Saraswat & Anjana Goel, 2024; Zsuzsánna Réthi-Nagy & Szilvia Juhász, 2024).

Advances in metagenomic analysis

Metagenomic sequencing has significantly advanced the understanding of the microbiome's role in cancer by revealing the complex interactions between microbial communities and cancer development, progression, and treatment response. This approach has primarily focused on identifying specific microbes associated with various cancers, such as Helicobacter pylori with gastric cancer and Fusobacterium nucleatum with colorectal cancer, highlighting the microbiome's potential as a diagnostic and therapeutic target(İlhami KİZİROĞLU, 2023). However, the functional implications of these microbial communities remain underexplored, with metatranscriptomics offering a promising avenue to bridge this gap by analyzing the active roles of microbiomes in cancer environments("Microbiomes, Their Function, and Cancer: How Metatranscriptomics Can Close the Knowledge Gap," 2023). The integration of artificial intelligence (AI) into microbiome research addresses challenges such as large datasets, noise, and limitations of analytical tools. AI, particularly machine learning (ML) and deep learning (DL), enhances the interpretation of complex multi-omics data, facilitating precision oncology by identifying microbial patterns that influence cancer therapy outcomes(Miodrag Cekikj et al., 2022; Tamizhini Loganathan & George Priya Doss C, 2022). For instance, AI models like DeepMicroCancer and DeepGeni have demonstrated improved diagnostic accuracy across multiple cancer types and enhanced prediction of immunotherapy responses, respectively, by leveraging advanced techniques such as transfer learning and interpretable autoencoders(Teng Wang et al., 2023; Tewabe Edmew Worku, 2023). These models not only improve diagnostic capabilities but also provide insights into the molecular mechanisms of microbiome-cancer interactions, which are crucial for developing personalized treatment strategies(Carlos S. Casimiro-Soriguer et al., 2022; Natascha Brandhorst, 2022). Furthermore, AI-driven analyses have uncovered numerous associations between tumor microbiomes and host molecular aberrations, offering potential biomarkers for cancer prognosis and therapy optimization(Jiuxin Qu & Shimin Shuai, 2023). By addressing the inherent complexity and variability of microbiome data, AI facilitates a deeper understanding of the microbiome's role in cancer, paving the way for innovative therapeutic interventions and improved clinical outcomes(Nick Ting et al., 2022).

Role of AI in analyzing microbial influences on cancer

Artificial intelligence (AI), particularly machine learning (ML) and deep learning (DL), has significantly advanced the fields of microbial classification, disease association, and biomarker discovery in cancer research. These AI techniques enable the analysis of complex datasets, facilitating the identification of novel biomarkers and improving diagnostic accuracy. AI's ability to integrate and analyze diverse data types, such as genomics, microbiome, and imaging data, has expanded the potential for precision oncology. The following sections explore the contributions of AI in these areas, highlighting strengths and limitations.

Microbial Classification and Disease Association

Microbiome-Based Diagnosis: AI models, such as DeepMicroCancer, utilize random forest and transfer learning techniques to diagnose a broad spectrum of cancer types based on microbiome data. These models have shown superior performance in tissue and blood samples, indicating that specific microbial signatures can differentiate between cancerous and healthy states.

Microbe-Disease Associations: The DSAE_RF model combines multi-source features and deep learning to predict microbe-disease associations. This approach reduces the time and cost associated with biological experiments, achieving high accuracy in identifying disease-related microbes(Teng Wang et al., 2023).

Explainable AI for Biomarker Identification: Techniques like Shapley Additive Explanations (SHAP) provide personalized insights into colorectal cancer biomarkers by analyzing gut microbiome compositions, allowing for subgroup-specific biomarker identification(Ryza Rynazal, 2023).

Biomarker Discovery in Cancer Research

Genomic and Multi-Omics Data: AI methods have expanded biomarker discovery beyond genomics to include transcriptomics and epigenomics. These approaches have identified novel biomarkers for immune checkpoint inhibitors (ICI) and other cancer therapies, although prospective trials are needed for clinical integration(Arsela Prelaj et al., 2023).

Angiogenesis-Related Biomarkers: Recurrent neural networks (RNNs) have been effective in identifying angiogenesis-related biomarkers, which are crucial for understanding tumor biology and developing targeted therapies("Artificial Intelligence in Cancer Research: Predictive Modeling of Angiogenesis and Biomarker Discovery," 2024).

Strengths of AI Techniques

High Accuracy and Efficiency: AI models, such as those using convolutional neural networks (CNNs), achieve high accuracy in microbial identification and cancer classification, often surpassing traditional methods(Gao et al., 2024; Yuan-Gu Wei et al., 2023).

Integration of Diverse Data: AI's ability to integrate multimodal data, including genomics, radiomics, and pathomics, enhances the discovery of complex biomarkers and meta-biomarkers(Arsela Prelaj et al., 2023).

Personalized Medicine: AI facilitates personalized treatment strategies by identifying molecular subtypes and specific biomarkers, contributing to precision oncology(Ghufran Ahmed & Shahid Hussain, 2023).

Limitations and Challenges

Generalizability: Current AI models often face challenges in generalizing across different cancer types and sample sources, such as tissue versus blood(Teng Wang et al., 2023).

Clinical Integration: Despite promising results, many AI-based discoveries lack high-level evidence for immediate clinical application, necessitating further validation through prospective trials(Arsela Prelaj et al., 2023).

Complexity and Interpretability: The complexity of AI models can hinder their interpretability, making it difficult for clinicians to understand and trust AI-driven insights(Ryza Rynazal, 2023).

While AI techniques have demonstrated significant potential in advancing cancer research, challenges remain in their clinical application and generalizability. The integration of AI into clinical practice requires careful validation and consideration of ethical and interpretability issues. Nonetheless, AI continues to offer promising avenues for improving cancer diagnosis, treatment, and personalized medicine.

Challenges and future directions

The integration of artificial intelligence (AI) in cancer-related metagenomic analysis presents several challenges, particularly concerning AI models, data quality, and clinical applicability. One of the primary issues is the "black box" nature of AI, which limits transparency and interpretability, making it difficult for clinicians to trust and adopt these technologies in practice. This lack of interpretability is compounded by biases in AI models, which often arise from underrepresented populations in datasets, leading to healthcare disparities("Artificial Intelligence in Oncology: Current Capabilities, Future Opportunities, and Ethical Considerations," 2022). Additionally, the quality of data used in AI models is a significant concern. Metagenomic data, characterized by its high dimensionality and compositional nature, poses challenges in preprocessing and feature selection, which can affect the predictive performance of AI models(Georgios Papoutsoglou et al., 2023; Huriye Armağan Doğan, 2023). The complexity and sparsity of these datasets, often referred to as the "curse of dimensionality," further complicate the extraction of clinically meaningful insights(Doğan, 2023). Despite these challenges, there are promising opportunities for improvement. The development of explainable AI (xAI) models is crucial, as they can provide insights into the decision-making process of AI systems, thereby enhancing trust and facilitating clinical adoption(*AI in Healthcare: Applications, Challenges, and Future Prospects*, 2024; J. Keyl et al., 2023). Expanding and diversifying databases to include a broader range of genetic and environmental factors can help mitigate biases and improve the generalizability of AI models("Artificial Intelligence in Oncology: Current

Capabilities, Future Opportunities, and Ethical Considerations," 2022; Danishuddin et al., 2023). Furthermore, validating AI findings through rigorous clinical studies is essential to ensure their reliability and effectiveness in real-world settings(*AI in Healthcare: Applications, Challenges, and Future Prospects*, 2024; J. Keyl et al., 2023). The future of AI in cancer research lies in the integration of multimodal data and the development of living databases that continuously update with new health information, enabling more personalized and precise treatment strategies("Artificial Intelligence in Oncology: Current Capabilities, Future Opportunities, and Ethical Considerations," 2022; Xifeng Wu et al., 2023). By addressing these challenges and leveraging these opportunities, AI can significantly advance the field of oncology, leading to improved patient outcomes and a deeper understanding of cancer biology.

Conclusion

In conclusion, the review highlights the pivotal role of the microbiome in cancer development and the transformative potential of AI-driven metagenomic analysis. By addressing challenges such as data complexity and integration, AI enables deeper insights into microbial influences on cancer, aiding biomarker discovery and disease prediction. Continued advancements in AI models and multi-omics integration will pave the way for innovative diagnostics and personalized treatments, significantly advancing cancer research and patient care.

References:

1. *AI in Healthcare: Applications, Challenges, and Future Prospects*. (2024). https://doi.org/10.48047/resmil.v10i1.18
2. Arsela Prelaj, Veronika Mišković, M. Zanitti, F. Trovò, C. Genova, Giuseppe Viscardi, S.E. Rebuzzi, Laura Mazzeo, L. Provenzano, S. Kosta, M. Favali, Andrea Spagnoletti, Louis Castelo-Branco, J. Dolezal, A.T. Pearson, G. Lo Russo, Claudia Proto, Monica Ganzinelli, C. Giani, … Alessandro Pedrocchi. (2023). Artificial Intelligence for predictive biomarker discovery in immuno-oncology: A systematic review. *Annals of Oncology*. https://doi.org/10.1016/j.annonc.2023.10.125
3. Artificial Intelligence in Cancer Research: Predictive Modeling of Angiogenesis and Biomarker Discovery. (2024). *Journal of Angiotherapy*. https://doi.org/10.25163/angiotherapy.889975
4. Artificial Intelligence in Oncology: Current Capabilities, Future Opportunities, and Ethical Considerations. (2022). *American Society of*

Clinical Oncology Educational Book, *42*, 842–851. https://doi.org/10.1200/edbk_350652

5. Carlos S. Casimiro-Soriguer, Carlos Loucera, Maria Peña-Chilet, & Joaquín Dopazo. (2022). Towards a metagenomics machine learning interpretable model for understanding the transition from adenoma to colorectal cancer. *Dental Science Reports*, *12*(1). https://doi.org/10.1038/s41598-021-04182-y
6. Danishuddin, Shawez Khan, & Jong Joo Kim. (2023). From cancer big data to treatment: Artificial intelligence in cancer research. *Journal of Gene Medicine*, e3629–e3629. https://doi.org/10.1002/jgm.3629
7. Gao, B., Jiang, Y., Han, M., Ji, X., Zhang, D., Gao, X., Huang, S., Zhao, C., Su, Y., Yang, S., Zhang, X., Liu, N., Han, L., Wang, L., Ren, L., Yang, J., Wu, J., Yuan, Y., & Dai, P. (2024). Targeted Linked-Read Sequencing for Direct Haplotype Phasing of Parental GJB2/SLC26A4 / SLC26A4 Alleles. *JOURNAL OF MOLECULAR DIAGNOSTICS*, *26*(7), 638–651. https://doi.org/10.1016/j.jmoldx.2024.04.002
8. Georgios Papoutsoglou, Sonia Tarazona, Marta B. Lopes, Thomas Klammsteiner, Eliana Ibrahimi, Julia Eckenberger, Pierfrancesco Novielli, Alberto Tonda, Andrea Simeon, Rajesh Shigdel, Stéphane Béreux, Giacomo Vitali, Sabina Tangaro, Leo Lahti, A. Temko, Marcus J. Claesson, & Magali Berland. (2023). Machine learning approaches in microbiome research: Challenges and best practices. *Frontiers in Microbiology*. https://doi.org/10.3389/fmicb.2023.1261889
9. Ghufran Ahmed & Shahid Hussain. (2023). *A Survey on Cancer Molecular Subtype Classification using Deep learning*. 1–5. https://doi.org/10.1109/iCoMET57998.2023.10099055
10. Haohong Zhang, Xinghao Xiong, Mingyue Cheng, Lei Ji, & Kang Ning. (2024). Deep learning enabled integration of tumor microenvironment microbial profiles and host gene expressions for interpretable survival subtyping in diverse types of cancers. *MSystems*, e0139524–e0139524. https://doi.org/10.1128/msystems.01395-24
11. Huriye Armağan Doğan. (2023). *Human interpretable artificial intelligence applications for microbial-related diseases*. https://doi.org/10.51415/10321/4701
12. İlhami KİZİROĞLU. (2023). *Artificial Intelligence Application to Microbiomics Data for Improved Clinical Decision Making in Precision Oncology* (pp. 157–177). https://doi.org/10.1007/978-3-031-21506-3_8

13. Istuti Saraswat & Anjana Goel. (2024). Therapeutic Modulation of the Microbiome in Oncology: Current Trends and Future Directions. *Current Pharmaceutical Biotechnology*, *26*. https://doi.org/10.2174/0113892010353600241109132441

14. Ivania Valdés, Alberto Martin, Eduardo Martínez, Daniel Carvajal Hausdorf, & Erick Riquelme. (2024). Abstract 1280: Role of the tumor microbiome in the lung adenocarcinoma immune microenvironment through multi meta-omics analysis. *Cancer Research*. https://doi.org/10.1158/1538-7445.am2024-1280

15. J. Keyl, Philipp Keyl, Grégoire Montavon, René Hosch, Alexandra Brehmer, Liliana Mochmann, Philipp Jurmeister, Gabriel Dernbach, Moon Kim, Sven Koitka, Sebastian Bauer, Nikolaos Bechrakis, Michael Forsting, -. DagmarFührer, Sakel, Martin Glas, Viktor Grünwald, Boris Hadaschik, Johannes, … Jens Kleesiek. (2023). Decoding pan-cancer treatment outcomes using multimodal real-world data and explainable artificial intelligence. *medRxiv*. https://doi.org/10.1101/2023.10.12.23296873

16. Jiuxin Qu & Shimin Shuai. (2023). Pan-cancer analysis reveals tumor microbiome associations with host molecular aberrations. *bioRxiv*. https://doi.org/10.1101/2023.04.13.536730

17. Liu, Y., Yoshizawa, A. C., Ling, Y., & Okuda, S. (2024). Insights into predicting small molecule retention times in liquid chromatography using deep learning. *Journal of Cheminformatics*, *16*(1), 113. https://doi.org/10.1186/s13321-024-00905-1

18. *Machine Learning on Microbiome Research in Gastrointestinal Cancer* (pp. 193–200). (2023). https://doi.org/10.1007/978-981-19-4492-5_13

19. Md. Fakruddin, Md. Asaduzzaman Shishir, Israk Iram Oyshe, S.M. Tasbir Amin, Amana Hossain, Israt Jahan Sarna, Nusrat Jerin, & Dipak Kumar Mitra. (2023). Microbial Architects of Malignancy: Exploring the Gut Microbiome's Influence in Cancer Initiation and Progression. *Cancer Plus*. https://doi.org/10.18063/cp.397

20. Microbiomes, Their Function, and Cancer: How Metatranscriptomics Can Close the Knowledge Gap. (2023). *International Journal of Molecular Sciences*. https://doi.org/10.3390/ijms241813786

21. Miodrag Cekikj, Milena Jakimovska Özdemir, Slobodan Kalajdzhiski, Orhan Özcan, & Ugur Sezerman. (2022). Understanding the

Role of the Microbiome in Cancer Diagnostics and Therapeutics by Creating and Utilizing ML Models. *Applied Sciences*, *12*(9), 4094–4094. https://doi.org/10.3390/app12094094

22. Natascha Brandhorst. (2022). The microbiome and precision oncology: An emerging paradigm in anticancer therapy. *Critical Reviews In Microbiology*, *48*(6), 770–783. https://doi.org/10.1080/1040841x.2022.2035313
23. Nick Ting, Harry Cheuk Hay Lau, & Jun Yu. (2022). Cancer pharmacomicrobiomics: Targeting microbiota to optimise cancer therapy outcomes. *Gut*, *71*(7), 1412–1425. https://doi.org/10.1136/gutjnl-2021-326264
24. Pan-Cancer Analysis of Microbiome Quantitative Trait Loci. (2022). *Cancer Research*, *82*(19), 3449–3456. https://doi.org/10.1158/0008-5472.can-22-1854
25. Ryza Rynazal. (2023). *Leveraging explainable AI for gut microbiome-based colorectal cancer classification*. https://doi.org/10.52843/cassyni.pm26b6
26. Saksham Garg, Nikita Sharma, Bharmjeet, & Asmita Das. (2023). Unraveling the intricate relationship: Influence of microbiome on the host immune system in carcinogenesis. *Cancer Reports*, e1892–e1892. https://doi.org/10.1002/cnr2.1892
27. Sona Ciernikova, Aneta Sevcikova, Beata Mladosievicova, & Michal Mego. (2023). Microbiome in Cancer Development and Treatment. *Microorganisms*. https://doi.org/10.3390/microorganisms12010024
28. Tamizhini Loganathan & George Priya Doss C. (2022). The influence of machine learning technologies in gut microbiome research and cancer studies—A review. *Life Sciences*, *311 Pt A*, 121118–121118. https://doi.org/10.1016/j.lfs.2022.121118
29. Teng Wang, Nan Wang, Haohong Zhang, Yuguo Zha, Yuwen Chu, & Kang Ning. (2023). Artificial intelligence-enabled microbiome-based diagnosis models for a broad spectrum of cancer types. *Briefings in Bioinformatics*, *24*(3). https://doi.org/10.1093/bib/bbad178
30. Tewabe Edmew Worku. (2023). DeepGeni: Deep generalized interpretable autoencoder elucidates gut microbiota for better cancer immunotherapy. *Dental Science Reports*, *13*(1). https://doi.org/10.1038/s41598-023-31210-w
31. Veeksha V Shetty & Shilpa S. Shetty. (2024). Exploring the gut microbiome and head and neck cancer interplay. *Pathology Research*

and Practice, *263*, 155603–155603. https://doi.org/10.1016/j.prp.2024.155603

32. Xifeng Wu, Wenyuan Li, & Huakang Tu. (2023). Big data and artificial intelligence in cancer research. *Trends in Cancer*. https://doi.org/10.1016/j.trecan.2023.10.006
33. Yuan-Gu Wei, Meiyan Gao, Jun Xiao, Chi-Hung Liu, Yupeng Tian, & Yaru He. (2023). Research and Implementation of Cancer Gene Data Classification Based on Deep Learning. *Journal of Software Engineering and Applications*, *16*(06), 155–169. https://doi.org/10.4236/jsea.2023.166009
34. Zahraa Rahal, Yuejiang Liu, Fuduan Peng, Matthew Ross, Ansam Sinjab, Ke Liang, Jiping Feng, Chidera O. Chukwuocha, Manvi Sharma, Elizabeth L. Tang, Camille Abaya, Joseph Petrosino, Junya Fujimoto, Seyed Javad Moghaddam, Linghua Wang, Kristi L Hoffman, & Humam Kadara. (2023). *1330 Gut microbiome dysbiosis promotes immune suppression and lung cancer development*. https://doi.org/10.1136/jitc-2023-sitc2023.1330
35. Zhou Chen, Defeng Guan, Zheng Wang, Xin Liu, Shi-Zhen Dong, Junjun Huang, & Wence Zhou. (2023). Microbiota in cancer: Molecular mechanisms and therapeutic interventions. *MedComm*, *4*. https://doi.org/10.1002/mco2.417
36. Zsuzsánna Réthi-Nagy & Szilvia Juhász. (2024). Microbiome's Universe: Impact on health, disease and cancer treatment. *Journal of Biotechnology*. https://doi.org/10.1016/j.jbiotec.2024.07.002
37. Zuzanna Chilimoniuk, Dominik Dudziński, Aleksandra Borkowska, Aleksandra Chałupnik, Piotr Więsyk, Beata Chilimoniuk, Łukasz Gawłowicz, Filip Grzegorzak, & Katarzyna Stasiak. (2024). Correlation between gut microbiota dysbiosis and colorectal cancer: Review. *Quality in Sport*, *22*, 54326–54326. https://doi.org/10.12775/qs.2024.22.54326
38. Л. Г. Соленова, Н. И. Рыжова, I. A. Antonova, Gennady A. Belitsky, Kirill Kirsanov, & Marianna G. Yakubovskaya. (2024). Features of the microbiota for various malignant neoplasms. *Issledovaniâ i Praktika v Medicine*, *11*(3), 85–102. https://doi.org/10.17709/2410-1893-2024-11-3-7

MUNDARIJA | TABLE OF CONTENTS | СОДЕРЖАНИЕ